Dados do Trabalho

Título

Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder

Resumo

Introduction:Cannabidiol (CBD) is one of the main non-psychoactive components of Cannabis sativa and may represent an alternative route for treating REM sleep behavior disorder (RBD). Methods: a phase II/III, double-blind, placebo-controlled clinical trial was conducted in 33 patients with RBD associated with Parkinson's disease (PD). Patients were randomized to CBD in doses of 75 to 300mg or matched capsules placebo and were followed up for 14 weeks. Primary outcomes were the frequency of nights with RBD, CGI-I, and CGI-S. Results: CBD showed no difference in relation to placebo for primary outcomes. Regarding secondary outcomes, we observed a significant improvement in average sleep satisfaction from the 4th to 8th week in the CBD versus placebo group with p=0.049 and p=0.038, respectively. Conclusion: CBD, as an adjunct therapy, showed no reduction in RBD manifestation. An improvement in sleep satisfaction with doses of 75-150mg has been noted.

Palavras Chave

Sleep; Cannabidiol, REM sleep behavioral disorder, Parkinson's disease.